Objective: To discuss the curative efficacy of Shugan Tiaoxin decoction and its influence to on serous inflammatory factors in treating malignant tumor combined with depression. Method: One hundred and ten eligible patients were randomly divided into control group (55 cases) and observation group (55 cases) by random number table. Patients in control group received Fluoxetine capsules (starting dose was 20 mg/day

taken after breakfast

and the dose was adjusted according to patients' state after 2 weeks). Based on the treatment of control group

patients in observation group added 1 dose Shugan Tiaoxin decoction daily. Patients in two groups received a 8-week period of treatment. Before and after treatment

the Hamilton depression rating scale (HAMD) and the self-rating depression scale were graded. The quality of life scale (QLQ-BR30) of European Organization for Research and Treatment of Cancer (EORTC) was graded. Levels of serous interleukin-1β (IL-1β)

interleukin-2 (IL-2)

interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were detected. Result: The depressant action in observation group was superior to that in control group (P<0.05)

and depression symptom in observation group was better than that in control group(P<0.01)

and scores of HAMD and SDS in observation group were lower than those in control group (P<0.01). Scores of role function

emotional function and global quality of life in observation group were all higher than those in control group (P<0.05

P<0.01). Scores of pain

insomnia

appetite loss

constipation and diarrhea in observation group were lower than those in control group (P<0.05

P<0.01). Levels of IL-1β

IL-6 and TNF-α in observation group were lower than those in control group

and level of IL-2 was higher than that in control group (P<0.01). Conclusion: Shugan Tiaoxin decoction could ameliorate depression symptom

reduce symptoms of depression and improve patients' quality of life in treating malignant tumor combined with depression. Its mechanism of action may be related to the regulation of serous inflammatory factors.